Edesa Biotech Stock Revenue
| EDSA Stock | USD 1.78 0.12 6.32% |
Edesa Biotech fundamentals help investors to digest information that contributes to Edesa Biotech's financial success or failures. It also enables traders to predict the movement of Edesa Stock. The fundamental analysis module provides a way to measure Edesa Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Edesa Biotech stock.
| Last Reported | Projected for Next Year |
Edesa | Revenue |
Edesa Biotech Company Revenue Analysis
Edesa Biotech's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Edesa
Projected quarterly revenue analysis of Edesa Biotech provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Edesa Biotech match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Edesa Biotech's stock price.
Edesa Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Edesa Biotech is extremely important. It helps to project a fair market value of Edesa Stock properly, considering its historical fundamentals such as Revenue. Since Edesa Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Edesa Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Edesa Biotech's interrelated accounts and indicators.
| 0.08 | 0.19 | -0.3 | 0.09 | 0.4 | ||
| 0.08 | 0.76 | -0.37 | 0.37 | 0.68 | ||
| 0.19 | 0.76 | -0.01 | 0.62 | 0.53 | ||
| -0.3 | -0.37 | -0.01 | 0.15 | -0.69 | ||
| 0.09 | 0.37 | 0.62 | 0.15 | 0.16 | ||
| 0.4 | 0.68 | 0.53 | -0.69 | 0.16 |
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Edesa Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Edesa Biotech reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Edesa Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Edesa Biotech's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Edesa Biotech could also be used in its relative valuation, which is a method of valuing Edesa Biotech by comparing valuation metrics of similar companies.Edesa Biotech is currently under evaluation in revenue category among its peers.
Edesa Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Edesa Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Edesa Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Edesa Biotech's value.| Shares | Federation Des Caisses Desjardins Du Quebec | 2024-09-30 | 19.0 | Bank Of America Corp | 2024-09-30 | 19.0 | Ubs Group Ag | 2024-09-30 | 4.0 | Crédit Agricole S.a. | 2024-09-30 | 1.0 | Allsquare Wealth Management Llc | 2024-09-30 | 1.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Fmr Inc | 2024-06-30 | 0.0 | Cibc World Markets Inc. | 2024-09-30 | 0.0 | Cm Management, Llc | 2024-09-30 | 110 K | Geode Capital Management, Llc | 2024-09-30 | 20.8 K | Vanguard Group Inc | 2024-09-30 | 15.9 K |
Edesa Fundamentals
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | 3.78 M | ||||
| Shares Outstanding | 3.25 M | ||||
| Shares Owned By Insiders | 33.22 % | ||||
| Shares Owned By Institutions | 12.19 % | ||||
| Number Of Shares Shorted | 35.49 K | ||||
| Price To Earning | (3.96) X | ||||
| Price To Book | 2.02 X | ||||
| Price To Sales | 120,478 X | ||||
| Gross Profit | 311.2 K | ||||
| EBITDA | (9.22 M) | ||||
| Net Income | (8.37 M) | ||||
| Cash And Equivalents | 12.81 M | ||||
| Cash Per Share | 0.83 X | ||||
| Total Debt | 94.49 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 0.88 X | ||||
| Cash Flow From Operations | (6.64 M) | ||||
| Short Ratio | 0.76 X | ||||
| Earnings Per Share | (19.78) X | ||||
| Target Price | 20.5 | ||||
| Number Of Employees | 16 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 5.78 M | ||||
| Total Asset | 8.89 M | ||||
| Retained Earnings | (52.42 M) | ||||
| Working Capital | 4.61 M | ||||
| Current Asset | 6.92 M | ||||
| Current Liabilities | 581.49 K | ||||
| Net Asset | 8.89 M |
About Edesa Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Edesa Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Edesa Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Edesa Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock:Check out Edesa Biotech Piotroski F Score and Edesa Biotech Altman Z Score analysis. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.78) | Quarterly Revenue Growth (1.00) | Return On Assets (0.72) | Return On Equity (1.29) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.